US/UK/Canada

Share

Pick a time period -
Tags ( Active)

Increase of number of shares and votes in Vicore Pharma

Stockholm, December 30, 2022– Vicore Pharma Holding AB (publ) (“Vicore” or the “company”)’s registered share capital and number of outstanding shares and votes have increased during the month of December 2022.As previously announced, the company’s board of directors resolved on a directed share issue of 10,000,000 shares at a subscription price of SEK 20.00 per share on December 8, 2022. Through the share issue, Vicore received issue proceeds of 200 MSEK before issue costs. As of today, the total number of registered and outstanding shares and votes of Vicore amounts to 81,847,979.

Vicore has carried out a directed share issue of 10,000,000 shares at a subscription price of SEK 20 per share, raising gross proceeds of SEK 200 million

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, NEW ZEALAND, HONG KONG, JAPAN OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES. Stockholm, 8 December 2022 – Vicore Pharma Holding AB (publ) (“Vicore” or the “Company”), a pioneer in the development of angiotensin II type 2 receptor agonists (ATRAGs), has completed a directed share issue of 10,000,000 shares at a subscription price of SEK 20 per share (the “

Vicore intends to carry out a directed share issue

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, NEW ZEALAND, HONG KONG, JAPAN OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES. Stockholm, 7 December 2022 – Vicore Pharma Holding AB (publ) (“Vicore” or the “Company”), a pioneer in the development of angiotensin II type 2 receptor agonists (ATRAGs), announces its intention to carry out a directed share issue corresponding to approximately 10 million shares

Vicore announces first patient enrolled in COMPANION; a digital therapeutic pivotal study for patients with pulmonary fibrosis

· First randomized clinical investigation with a digital therapy (DTx) to address the psychological symptom burden in pulmonary fibrosis (PF) patients · First patient enrolled in US pivotal study; readout expected Q4 2023 · Supports development of a strong holistic portfolio in rare lung disease Stockholm, December 5, 2022 – Vicore Pharma Holding AB (publ) (“Vicore”), a pioneer in the development of angiotensin II type 2 receptor agonists (ATRAGs), today launched the pivotal phase of COMPANION, the first clinical investigation of a digital cognitive behavioral therapy (dCBT) for

Vicore announces new data from the IPF AIR trial further strengthening the benefit-risk profile of C21

· The new results show stabilization of disease already from week 6 and confirm the unprecedented increase in lung function over time · Vicore will accelerate clinical development · Invitation to conference call on November 4 at 13:00 CET/8:00 am EST Stockholm, November 3, 2022 – Vicore Pharma Holding AB (publ) (“Vicore” or the “Company”), a pioneer in the development of angiotensin II type 2 receptor agonists (ATRAGs), provides a new interim analysis of the ongoing AIR trial, a phase 2a study in idiopathic pulmonary fibrosis (IPF). The AIR trial[1] is a multi-center open label

Interim report July-September 2022

Stockholm, November 3, 2022 - Vicore Pharma Holding AB (publ) publishes the interim report for the third quarter 2022.Important events during the third quarter · In August, Vicore announced late-breaker presentation of interim data with C21 in the IPF trial (AIR) at the 2022 ERS congress. · In September, Vicore announced continued stabilization and increase in lung capacity with C21 in the IPF trial (AIR) and a second interim analysis planned for Q4 2022. · In September, Vicore announced that the phase 3 trial with C21 in COVID-19 (ATTRACT-3) did not reach the primary and

Vicore announces the Nomination Committee for the 2023 Annual General Meeting

Gothenburg, October 20, 2022 – Vicore Pharma Holding AB (publ) (“Vicore”) has appointed the Nomination Committee for the 2023 Annual General Meeting. The three largest shareholders as of August 31, 2022 have been offered to appoint a member to the Nomination Committee each, in accordance with the decision taken at the Annual General Meeting on May 11, 2021.The Nomination Committee consists of Staffan Lindstrand, appointed by HealthCap VII L.P., Jan Särlvik, appointed by the Fourth Swedish National Pension Fund and Ivo Staijen appointed by HBM Healthcare Investments (Cayman) Ltd. Vicore’s

Vicore selects new ATRAG as next Drug Candidate

· C103, an angiotensin II type 2 receptor (AT2R) agonist (ATRAG), has been selected as Drug Candidate · The compound has a very high selectivity for the AT2R over the AT1R · A phase 1 trial is expected to start in H2-2023 Gothenburg, October 12, 2022 – Vicore Pharma Holding AB (publ) (“Vicore”), pioneering development of angiotensin II type 2 receptor agonists (ATRAGs), today announces that the compound C103 has been selected as the company’s third ATRAG drug candidate to move forward into toxicology studies and thereafter a phase 1 trial.  In preclinical testing, C103 has shown

Vicore’s digital therapeutic for IPF patients shows nearly 50% anxiety reduction in pilot study

· Analyses of safety, functionality and user acceptance was positive · Reported decrease in anxiety scores for patients with pulmonary fibrosis · COMPANION, a pivotal study in 250 patients with pulmonary fibrosis, to be initiated in Q4 2022 Gothenburg, October 6, 2022 – Vicore Pharma Holding AB (publ) (“Vicore”) pioneering development of angiotensin II type 2 receptor agonists (ATRAGs), today announces positive results for the pilot phase of the COMPANION study. Vicore’s digital Cognitive Behavioral Therapy (CBT) therapy, Almee[TM]; for patients with pulmonary fibrosis was safe,

Vicore announces that C21 promotes vascular function in humans

· Clinically relevant doses of C21 increase blood flow in humans · Systemic blood pressure was unaffected, and no side effects were observed · The forearm blood flow method is a robust technique for early clinical concept testing Gothenburg, September 22, 2022 – Vicore Pharma Holding AB (publ) (“Vicore”), a clinical-stage pharmaceutical company developing medicines stimulating the angiotensin II type 2 receptor (AT2R), today announces that intra-arterial administration of C21 results in a significant dose-dependent increase in local blood flow.  Forearm blood flow was measured

Vicore provides an update on the ATTRACT-3 COVID-19 trial

· ATTRACT-3 did not meet its primary endpoint, reduction of all-cause mortality at 60 days · Lack of effect explained by new virus mutations · No safety signals detected   · The company will focus the development of C21 for the treatment of IPF and PAH Gothenburg, September 15, 2022 – Vicore Pharma Holding AB (publ) (“Vicore”), a clinical-stage pharmaceutical company developing medicines targeting the angiotensin II type 2 receptor (AT2R), today announces the top-line data from the ATTRACT-3 trial in hospitalized COVID-19 patients.  In ATTRACT-3[1], a global phase 3 trial,

Vicore update on the AIR phase 2 trial in idiopathic pulmonary fibrosis

· The previously reported February interim analysis will be presented as a late breaker at the ERS congress · Observations of continued stabilization and increase in lung capacity · A second interim analysis and update on the development program are planned for Q4 2022 Gothenburg, September 2, 2022 – Vicore Pharma Holding AB (publ) (“Vicore”), a clinical-stage pharmaceutical company developing medicines targeting the angiotensin II type 2 receptor (AT2R), gives a short update and informs about upcoming events in the AIR trial, a phase 2 trial in idiopathic pulmonary fibrosis (IPF).

Interim report April - June 2022

Gothenburg, August 25, 2022 - Vicore Pharma Holding AB (publ) publishes the interim report for the second quarter 2022.Important events during the second quarter · In April, Vicore announced that the first patient in the clinical investigation of the digital therapeutic (DTx) in IPF was enrolled. · In April, Vicore submitted a clinical trial application (CTA) to start a phase 1 trial with the new drug candidate (C106) from the VP03 program. · In June, Vicore announced an amendment of the primary endpoint to all-cause mortality and a reduced sample size in the phase 3 trial in

Vicore announces multiple scientific abstracts and presentations at upcoming conferences during the autumn

Gothenburg, August 19, 2022 – Vicore Pharma Holding AB (publ) (“Vicore”), a clinical-stage pharmaceutical company developing medicines targeting the angiotensin II type 2 receptor (AT2R), today announces that it will present updates on the company’s progress and scientific results at meetings to be held in August, September and October 2022.Elin Rosendahl, VP Clinical Development, will present a poster entitled “Investigation of the effect of the angiotensin II type 2 receptor (AT2R) agonist C21 on plasma NT-proBNP, a diagnostic biomarker, in subjects hospitalised with COVID-19” at the

Vicore IPF interim data selected as an oral “late-breaker” at the ERS congress

· The AIR trial is a single arm, multicenter phase 2 study in patients with idiopathic pulmonary fibrosis (IPF) · Interim data have shown stabilization of the disease and an increase in lung capacity at 24 and 36 weeks · Oral presentation by Professor Toby Maher on September 4 at 15:00 CET   Gothenburg, August 17, 2022 - Vicore Pharma Holding AB (publ) (“Vicore”), a clinical-stage pharmaceutical company developing medicines targeting the angiotensin II type 2 receptor (AT2R), today announces that the previously published interim data from AIR, a phase 2 trial in IPF), will be

Increase of number of shares and votes in Vicore Pharma

Gothenburg, June 30, 2022– Vicore Pharma Holding AB (publ)’s registered share capital and number of outstanding shares and votes have increased during the month of June 2022.As previously announced, the Company’s board of directors resolved on a set-off issue of 87,686 shares at a subscription price of SEK 34.21 per share on June 17, 2022. The set-off issue was carried out as part of a milestone payment to the company's collaboration partners Emeriti Bio AB and HaLaCore Pharma AB, for the start of a phase 1 trial with C106. As of today, the total number of registered and outstanding

Vicore resolves on a set-off issue of 87,686 shares as part of milestone compensation

· Milestone compensation to collaboration partners in connection with the first patient dosed with C106. · One-time payment to the company's collaboration partners Emeriti Bio and HaLaCore Pharma in a total of approximately 6 MSEK, of which 3 MSEK in cash compensation and 87,686 newly issued shares in Vicore corresponding to approximately 3 MSEK. Gothenburg, June 17, 2022 - Vicore Pharma Holding AB (publ) (“Vicore”), a clinical-stage pharmaceutical company developing medicines targeting the angiotensin II type 2 receptor (AT2R), has today resolved on a set-off issue of 87,686 shares

Vicore announces first human dosed with novel ATRAG, C106

· First healthy volunteer dosed with C106 in a phase 1 trial · C106 is the first new angiotensin II type 2 receptor agonist (ATRAG) from Vicore’s VP03 program · Topline data expected Q1 2023 Gothenburg, June 16, 2022 - Vicore Pharma Holding AB (publ) (“Vicore”), a clinical-stage pharmaceutical company developing medicines targeting the angiotensin II type 2 receptor (AT2R), today announces initiation of a first-in-human trial with the novel ATRAG C106. The trial is expected to read out during Q1 2023.  Vicore’s C106 is the first of four advanced candidate drugs from the VP03

Vicore amends primary endpoint to accelerate the Phase 3 trial in COVID-19 patients

· Based on the profile of C21 and emerging COVID-19 data, the ongoing Phase 3 trial has been amended to revise the primary endpoint and reduce sample size · The amendment has been adopted to reflect the current SARS-CoV-2 virus landscape and will accelerate study completion · Expected read-out during Q3 2022 Gothenburg, June 3, 2022 - Vicore Pharma Holding AB (publ) (“Vicore”), a clinical-stage pharmaceutical company developing medicines targeting the angiotensin II type 2 receptor (AT2R), today announces an amendment of the ongoing COVID-19 Phase 3 trial (ATTRACT-3). In

Bulletin from the annual general meeting of Vicore Pharma Holding AB (publ)

The following resolutions were passed at the annual general meeting (the “AGM”) of Vicore Pharma Holding AB (publ) on 11 May 2022. Adoption of income statement and balance sheet for the financial year 2021 and discharge from liability The AGM resolved to adopt the income statement and the consolidated income statement for the financial year 2021 as well as the balance sheet and consolidated balance sheet as of 31 December 2021. The members of the board of directors and the managing director were discharged from liability for the financial year 2021. Allocation of profit or loss

Interim report January - March 2022

Gothenburg, May 5, 2022 - Vicore Pharma Holding AB (publ) publishes the interim report for the first quarter 2022.Important events during the first quarter · In February, an interim analysis of the AIR phase 2 trial in idiopathic pulmonary fibrosis (IPF) suggested that C21 stabilizes disease and shows an unanticipated increase in lung function in IPF patients. · In February, Vicore announced the advancement of its first new chemical entity (C106) from the VP03 program to a first in human phase 1 trial. · In March, Vicore announced the plan to initiate a proof-of-concept trial

Vicore launches COMPANION, a clinical study investigating the benefit of digital therapy on anxiety in patients with idiopathic pulmonary fibrosis (IPF)

· First clinical study with a digital therapy (DTx) in patients with IPF to address the psychological symptom burden in this disease · First patient enrolled in US pilot phase leading up to the US pivotal phase of the study with expected start in H2 2022 · DTx aims to form a part of a differentiated offering in rare lung disease Gothenburg, April 21, 2022 – Vicore Pharma Holding AB (publ) (“Vicore”), a clinical-stage pharmaceutical company, today announces the first patient enrolled in the pilot phase of COMPANION[1], a clinical study of a digital cognitive behavioral therapy for

Notice of annual general meeting of Vicore Pharma Holding AB (publ)

The shareholders of Vicore Pharma Holding AB (publ), Reg. No. 556680-3804 (“Vicore Pharma”), with registered office in Gothenburg, are summoned to the annual general meeting on Wednesday 11 May 2022. Vicore Pharma’s annual general meeting will be carried out through advance voting (postal voting) only pursuant to temporary legislation. No meeting with the possibility to attend in person or to be represented by a proxy will take place. Hence, the meeting will be held without physical presence, in accordance with the procedures last year, and with no customary arrangements in connection

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Media